Arrowstreet Capital
PTGX icon

Arrowstreet Capital’s Protagonist Therapeutics PTGX Stock Holding History

Arrowstreet Capital’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.46M Buy
+44,529
New +$4.65M ﹤0.01% 1263
2026
Q1 		– Sell
-5,076
Closed -$443K – 2052
2025
Q4 		$443K Buy
+5,076
New +$415K ﹤0.01% 1701
2025
Q3 		– Sell
-17,856
Closed -$987K – 2071
2025
Q2 		$987K Buy
+17,856
New +$857K ﹤0.01% 1616
2025
Q1 		– Sell
-216,069
Closed -$8.34M – 1970
2024
Q4 		$8.34M Buy
216,069
+58,002
+37% +$2.53M 0.01% 872
2024
Q3 		$7.11M Buy
+158,067
New +$6.39M 0.01% 859
2023
Q3 		– Sell
-14,895
Closed -$411K – 1388
2023
Q2 		$411K Buy
+14,895
New +$373K ﹤0.01% 1084
2020
Q4 		– Sell
-66,928
Closed -$1.31M – 2487
2020
Q3 		$1.31M Sell
66,928
-17,489
-21% -$328K ﹤0.01% 1736
2020
Q2 		$1.49M Buy
+84,417
New +$1.06M ﹤0.01% 1602
2020
Q1 		– Sell
-20,000
Closed -$141K – 2067
2019
Q4 		$141K Buy
+20,000
New +$199K ﹤0.01% 1645
2019
Q1 		– Sell
-28,602
Closed -$192K – 1872
2018
Q4 		$192K Sell
28,602
-63,439
-69% -$503K ﹤0.01% 1256
2018
Q3 		$947K Buy
92,041
+8,700
+10% +$74.9K ﹤0.01% 811
2018
Q2 		$560K Buy
+83,341
New +$640K ﹤0.01% 899

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Arrowstreet Capital's PTGX Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 44,529 shares worth $5.46M. The stake represents ﹤0.01% of the portfolio and ranks #1263 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in PTGX as recently as Q4 2025.

Arrowstreet Capital first reported a position in PTGX in Q2 2018 and has held it in 12 quarters since. The position peaked at $8.34M in Q4 2024. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Arrowstreet Capital held 44,529 shares of Protagonist Therapeutics worth $5.46M as of Q2 2026.
  • Protagonist Therapeutics was a new Arrowstreet Capital position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1263 holding.
  • Arrowstreet Capital first reported a position in Protagonist Therapeutics in Q2 2018 and has held it in 12 quarters since.
  • Arrowstreet Capital's Protagonist Therapeutics position peaked at $8.34M in Q4 2024.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.